LEGN - Legend Biotech Corporation (LEGN) Q1 2024 Earnings Call Transcript
2024-05-13 12:13:02 ET
Legend Biotech Corporation (LEGN)
Q1 2024 Earnings Call Transcript
May 13, 2024 08:00 AM ET
Company Participants
Jessie Yeung - Head of Investor Relations and Public Relations
Ying Huang - Chief Executive Officer
Lori Macomber - Chief Financial Officer
Guowei Fang - Chief Scientific Officer and Head of Business Development
Steve Gavel - Senior Vice President, Commercial Development, US and Europe
Conference Call Participants
Jessica Fye - J.P. Morgan
Gena Wang - Barclays
Kelly Shi - Jefferies
Omar Saad - Evercore ISI
Yaron Werber - TD Cowen
Ziyi Chen - Goldman Sachs
Leonid Timashev - RBC Capital Markets
Vikram Purohit - Morgan Stanley
Kostas Biliouris - BMO Capital Markets
George Farmer - Scotiabank
Justin Zelin - BTIG
Ashwani Verma - UBS
Sean McCutcheon - Raymond James
Mitchell Kapoor - H.C. Wainwright
Rick Bienkowski - Cantor Fitzgerald
Presentation
Operator
Good day, ladies and gentlemen, thank you for standing by. Welcome to Legend Biotech First Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speakers presentation there will be a question-and-answer session. [Operator Instructions] Please note that today's conference may be recorded.
I will now hand the conference over to your speaker host, Jessie Yeung, Head of Investor Relations and Public Relations. Please go ahead.
Jessie Yeung
Good morning. This is Jessie Yeung, Head of Investor Relations and Public Relations at Legend Biotech. Thank you for joining our conference call today to review our first quarter 2024 performance.
Joining me on today's call are Ying Huang, the company's Chief Executive Officer; and Lori Macomber, the company's Chief Financial Officer. Following their prepared remarks, we will open up the call for a Q&A. We have Guowei Fang, Chief Scientific Officer, and Steve Gavel, Head of Commercial Development for the US and Europe, joining the Q&A session.
During today's call, we will be making forward-looking statements, which are subject to risks and uncertainties that may cause our actual results to differ materially from those expressed or implied here within. These forward-looking statements are discussed in greater detail in our SEC filings, which we encourage you to read and can be found under the Investor's Session of our company website. Thank you.
Ying Huang
Hello, everyone, and welcome to our first quarter earnings call. I am pleased that you could join us. As many of you on this call know, 2024 has been an eventful year for us. Obviously, our major news was the approval of CARVYKTI by the FDA and the European Commission for second-line relapsed or refractory multiple myeloma. These approvals have the potential to change the treatment paradigm for tens of thousands of patients in the United States and Europe. The feedback from key opinion leaders, oncologists, advocates, patients, and caregivers has been tremendous.
On March 15th, we received international media attention when the FDA's Oncologic Drug Advisory Committee, or ODAC, meeting raised awareness about multiple myeloma and the positive benefit risk profile of CARVYKTI. ODAC's unanimous 11 to 0 recommendation in favor of CARVYKTI was independent and objective validation of its value proposition....
Legend Biotech Corporation (LEGN) Q1 2024 Earnings Call Transcript